Telix Pharmaceuticals (NASDAQ:TLX) Upgraded at Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $7.61 on Friday. The business’s 50-day moving average is $8.44 and its two-hundred day moving average is $10.36. Telix Pharmaceuticals has a 12 month low of $7.16 and a 12 month high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at approximately $297,000. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $3,037,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $975,000. Finally, Jane Street Group LLC bought a new position in Telix Pharmaceuticals during the second quarter worth $564,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.